Reason for request
Re-assessment of the actual benefit (AB) and the level of improvement in actual benefit (IAB) at the request of the applicant.
Clinical Benefit
| Low |
The actual benefit of MYOZYME remains low in the treatment of late-onset Pompe disease. |
Clinical Added Value
| minor |
The improvement in actual benefit remains minor (level IV) in the treatment of late-onset Pompe disease. |
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
zPGwY0FRJJvEunN1
Listen
